Cargando…

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

Programmed death-1 (PD-1) is an immunosuppressive receptor functionally bound with programmed death-ligand 1 (PD-L1), which has been reported in various malignancies. However, only a few studies are available for the clinical significance of PD-1/PD-L1 in nasopharyngeal carcinoma (NPC). In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yajuan, Shi, Dingbo, Miao, Jingjing, Wu, Haijun, Chen, Jiewei, Zhou, Xiaoyi, Hu, Desheng, Zhao, Chong, Deng, Wuguo, Xie, Conghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335261/ https://www.ncbi.nlm.nih.gov/pubmed/28256540 http://dx.doi.org/10.1038/srep43627

Ejemplares similares

PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes
por: Zhou, Yajuan, et al.
Publicado: (2017)

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
por: Bian, Jin, et al.
Publicado: (2022)

Retracted: A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Smith, Corey, et al.
Publicado: (2021)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
por: Tang, Yanyan, et al.
Publicado: (2017)

Analysis of Epstein–Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region
por: Dias, Josiane M., et al.
Publicado: (2022)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
por: Zheng, Jianpei, et al.
Publicado: (2023)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
por: Huang, Weijia, et al.
Publicado: (2022)

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015)

Survival Benefit of Adding Chemotherapy to Intensity Modulated Radiation in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Ji, Xuemei, et al.
Publicado: (2013)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

Differential expression of EBV proteins LMP1 and BHFR1 in EBV-associated gastric and nasopharyngeal cancer tissues
por: WANG, AILIANG, et al.
Publicado: (2016)

Intralesional EBV-DNA load as marker of prognosis for nasopharyngeal cancer
por: Nilsson, Johan S., et al.
Publicado: (2019)

Partial absence of PD‐1 expression by tumor‐infiltrating EBV‐specific CD8(+) T cells in EBV‐driven lymphoepithelioma‐like carcinoma
por: Simoni, Yannick, et al.
Publicado: (2020)

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
por: Makowska, Anna, et al.
Publicado: (2020)

The growth of non-solid neoplastic lung nodules is associated with low PD L1 expression, irrespective of sampling technique
por: Bortolotto, Chandra, et al.
Publicado: (2020)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

PTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer
por: Cao, Donghui, et al.
Publicado: (2022)

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Huang, Zi-Lu, et al.
Publicado: (2019)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
por: Dai, Zelei, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma
por: Zheng, Linfeng, et al.
Publicado: (2017)

Role of β-catenin in PD-L1 expression of nasopharyngeal carcinoma
por: Wang, Haihua, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms
por: Nakano, Hiroshi, et al.
Publicado: (2021)

PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
por: Lima, Áurea, et al.
Publicado: (2022)

PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival
por: Jimenez, Oscar, et al.
Publicado: (2022)

Friend Leukemia Virus Integration 1 Expression Has Prognostic Significance in Nasopharyngeal Carcinoma()
por: Liang, Xuexia, et al.
Publicado: (2014)

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
por: Zhang, Huilai, et al.
Publicado: (2023)

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
por: Qin, Ge, et al.
Publicado: (2020)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
por: Zeng, Zhen, et al.
Publicado: (2011)

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jung, Hae Il, et al.
Publicado: (2017)

PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis
por: ÖZDEMİR, Süleyman, et al.
Publicado: (2022)

PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients
por: Minichsdorfer, Christoph, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b9iet4mqde1c9nmidd97cmma14